- 专利标题： COMPOSITIONS AND METHODS FOR TREATMENT
-
申请号： US17815256申请日： 2022-07-27
-
公开(公告)号： US20230233551A1公开(公告)日： 2023-07-27
- 发明人: Thomas GADEK , John BURNIER
- 申请人： Novartis Pharmaceuticals Corporation
- 申请人地址： US NJ East Hanover
- 专利权人： Novartis Pharmaceuticals Corporation
- 当前专利权人： Novartis Pharmaceuticals Corporation
- 当前专利权人地址： US NJ East Hanover
- 分案原申请号： US13011760 2011.01.21
- 主分类号： A61K31/4725
- IPC分类号： A61K31/4725 ; C07D217/00 ; C07D217/02 ; A61K31/198 ; A61K31/404 ; A61K31/4162 ; A61K31/4184 ; A61K31/4192 ; A61K31/44 ; A61K31/4709 ; A61K31/4745 ; A61K31/496 ; A61K31/5377 ; A61K31/54 ; A61K31/541 ; A61P27/02 ; A61K31/381 ; A61K45/06 ; C07D333/38 ; C07D405/06 ; C07D405/14 ; C07D409/14 ; C07D471/04 ; A61K33/00 ; A61K33/06 ; C07D217/20 ; C07D217/06 ; A61K31/405 ; A61K31/495 ; A61K38/07 ; A61K38/08 ; A61K38/12 ; A61K38/17 ; G01N33/50 ; G01N33/68 ; A61K31/197 ; A61K31/341 ; A61K31/352 ; A61K31/472 ; C07D401/06 ; A61K31/275 ; A61K31/40 ; A61K31/517 ; C07C279/28 ; C07C317/50 ; C07D207/06 ; C07D217/26 ; C07D307/52 ; C07D413/14 ; A61K9/00 ; G01N33/566 ; A61B3/10 ; A61B3/14
摘要：
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
信息查询
IPC分类:
